We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call emphasized strong operational execution: pivotal Phase III LUCIDITY enrollment completed and on track for a Q3 2026 top-line readout, active NDA preparation, clear commercial planning (including an EAP for up to 250 patients), and multiple pipeline programs advancing (AMX0318 IND-enabling work, AMX0035 longer-term data, AMX0114 cohort progress). Financially, while the company has a cash position of $279.8M with runway into 2028, cash declined ~11.7% year-over-year and operating expenses increased (total operating expenses +16% YoY; R&D +24.9% YoY), driven by development and milestone payments—risks remain tied to the upcoming LUCIDITY result and the need to convert clinical success into regulatory approval and commercial uptake.
Management reiterated that avexitide’s pivotal Phase III LUCIDITY trial (90 mg once daily, 16‑week study; FDA‑agreed primary endpoint = composite of Level 2 [<54 mg/dL] and Level 3 hypoglycemic events) is fully enrolled, remains on track for a top‑line readout in Q3 2026, and that NDA preparations are underway with potential FDA approval and a commercial launch targeted in 2027; they also launched a U.S. expanded access program for up to 250 adults, estimate ~160,000 U.S. PBH patients after sleeve or Roux‑en‑Y surgery, and are building commercial and medical teams. Financials/guidance included $279.8M in cash and marketable securities (vs. $317M a year earlier) supporting a cash runway into 2028, Q1 operating expenses of $43.8M (up 16% year‑over‑year) with R&D $27.6M (vs. $22.1M) and SG&A $16.2M (vs. $15.7M), $6.1M non‑cash stock‑based comp (vs. $6.8M), and a $4M milestone paid to Gubra; other pipeline timelines noted: AMX0318 IND‑enabling work targeting a 2027 IND, AMX0035 week‑96 data planned for an upcoming meeting, and AMX0114 Cohort 2 fully enrolled with Cohort 1 biomarker data to be presented at ENCALS in June (LUCIDITY was powered ~90% and prior avexitide studies showed ~55% [PREVENT] and ~64% (90 mg) reductions, p=0.0031).
Randomized and dosed the last participant in late March; clear line of sight to complete the 16-week trial with top-line readout expected in Q3 2026. Study is powered at 90% and was designed to replicate prior positive trials (prior trials showed ~55% and 64% reductions in hypoglycemic events).
Avexitide has FDA Breakthrough Therapy designation; the company is actively drafting NDA sections now to accelerate a potential submission following top-line data, aiming to shorten typical post-Phase III timelines.
Active commercial preparations including hires across marketing, market access and commercial operations, and a disease-state education campaign planned for this summer. Independent claims analysis and field engagements support an estimated U.S. PBH population of ~160,000 people who underwent common bariatric surgeries. Company is preparing for potential commercialization in 2027 if approved.
U.S. expanded access program launched to provide avexitide for up to 250 adults with PBH (initially eligible: participants who completed LUCIDITY or prior avexitide trials), addressing urgent unmet need.
AMX0318: IND-enabling studies underway with a target 2027 IND filing and a $4.0M milestone recognized related to its selection as a development candidate. AMX0035: week-96 data from Phase II HELIOS in Wolfram syndrome expected to be presented at an upcoming meeting. AMX0114 (ALS): Cohort 2 of Phase I LUMINA fully enrolled; early biomarker data from Cohort 1 to be presented at ENCALS in June.
Cash and marketable securities of $279.8M at quarter end and management states this funds anticipated cash runway into 2028, covering key expected milestones including LUCIDITY top-line readout (Q3 2026) and potential FDA approval and commercial launch of avexitide in 2027.
Good morning. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsey Allen, Vice President, Investor Relations and Communications. Please proceed.
Good morning, and thank you all for joining us today to discuss our first quarter 2026 financial results and business update. With me on the call today are Josh Cohen and Justin Klee, our Co-CEOs; Dr. Camille Bedrosian, our Chief Medical Officer; Jim Frates, our Chief Financial Officer; and Dan Monahan, our Chief Commercial Officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to avexitide, AMX0035, AMX0114 and AMX0318, statements regarding regulatory and clinical developments and the impact thereof and the expected timing thereof and statements regarding our cash runway. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. You are cautioned not to place any undue reliance on these forward-looking statements, and Amy...